Year Founded
2000
Ownership
Public
Therapeutic Areas
OphthalmologyCardiovascularInfectious Diseases
Stage
Phase 1
Modalities
mRNA vaccineProtein therapeuticsSubunit vaccineVaccines (general)

EyeGene General Information

Developing vaccines and recombinant protein therapeutics, including COVID-19 vaccine candidates showing Omicron-specific neutralizing antibodies in preclinical studies

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
Uiwang-si, Gyeonggi-do
South Korea

Drug Pipeline

EG-Mirotin
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to EyeGene's pipeline data

Book a demo

Key Partnerships

BMI Korea Co., Ltd.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

EyeGene Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view EyeGene's complete valuation and funding history, request access »